STAT
DECEMBER 16, 2024
Lawmakers agreed to extend telehealth flexibilities, fund public health programs, and enact these major PBM changes as part of a government funding package they are planning to pass before the end of the year, according to four health care industry sources and two congressional aides. Continue to STAT+ to read the full story…
STAT
NOVEMBER 2, 2023
The package crafted by Senate Finance Chair Ron Wyden (D-Ore.) The pharmacy benefit manager regulations build on a separate package of PBM regulations that the panel passed in July. and Mike Crapo (R-Idaho) is slated to be marked up on Nov.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
MAY 11, 2023
WASHINGTON – The Senate health committee on Thursday passed a package of bills aimed at speeding generic drug competition and reining in drug middlemen business practices. is pursuing the drug pricing reforms at the behest of Senate Majority Leader Chuck Schumer (D-N.Y.), Chairman Bernie Sanders (I-Vt.)
STAT
OCTOBER 27, 2023
8 on legislation that includes substance abuse and mental health policies, reforms to drug middlemen’s business practices, and extensions to provider payment policies in Medicare and Medicaid, according to five health care lobbyists. WASHINGTON — The Senate Finance Committee plans to vote Nov. Read the rest…
STAT
DECEMBER 1, 2022
At a time when many Americans are clamoring for more transparency into prescription drug pricing, one key provider of that data is making it harder to access the information. This includes details such as separate doses and packaging on both current and historical prices. Continue to STAT+ to read the full story…
STAT
FEBRUARY 10, 2023
WASHINGTON — Generic drugmakers lobbied hard against Democrats’ new law empowering Medicare to negotiate prescription drug prices. Now that the changes are law, however, industry experts and lobbyists acknowledge the package is more of a mixed bag for generics makers like Teva and Sandoz, not an existential threat.
STAT
JULY 26, 2023
They’re focused this summer on reining in pharmacy middlemen to make the system fairer — but none of their many proposals will actually tackle the core dynamic that has incentivized higher drug prices. There are major packages on so-called PBM reform percolating in at least six different congressional committees.
Expert insights. Personalized for you.
336 
Let's personalize your content